2
"Sinopsis" puede pertenecer a otra edición de este libro.
The Billion-Dollar Molecule raises the curtain on the fascinating and tumultuous drama of a radically new start-up pharmaceutical company. That company, Vertex, is trying to design a lifesaving new drug that - if it works - will prove the potential of a brand-new drug-making technique and also fulfill the vision of Vertex's founder and chairman, Joshua Boger, one of the most promising scientists of his generation.
In early 1989 the thirty-seven-year-old Boger set out to revolutionize the drug industry, the most profitable industry in existence. Trained at Harvard and at Merck, the premier biomedical firm and perennially most admired corporation in America, Boger established Vertex to design drugs atom by atom.
Barry Werth takes readers inside Vertex from its first days to profile the driven, obsessive scientists who work around the clock in pursuit of scientific breakthroughs. One member of Vertex's scientific advisory board, Stuart Schreiber, is a full professor at Harvard, younger even than Boger, and determined to win a Nobel Prize and to create new molecules that will elucidate the workings of the human cell. Schreiber, however, soon becomes Boger's chief rival in a competition between emerging scientific titans.
The immediate goal for both Vertex and Schreiber is to explore the workings of a new immunosuppressant, a drug that prevents organ transplant rejections and that could have potentially wider uses. Only one approved immune-suppressing drug exists, and it has serious side effects. If Vertex can create a better drug, it will indeed be a billion-dollar molecule.
But to succeed, Vertex needs money, lots of it. Every biotechnology story is also a Wall Street story, and Boger spends much of his time raising capital. With the assistance of the dean of venture capitalists, Benno Schmidt, Sr., Boger and his colleagues woo foreign companies eager to find American partners to help expand their presence in the U.S. pharmaceutical market. Eventually Boger decides to take Vertex public in an anxious initial public offering where, characteristically, he dominates his financial advisers.
Meanwhile, the scientific story of the elusive target molecule proves to be more complex and surprising than even Boger imagined.
This is a no-holds-barred, brilliant and compelling look at one of the key industries of our future.
"Sobre este título" puede pertenecer a otra edición de este libro.
Gastos de envío:
GRATIS
A Estados Unidos de America
Gastos de envío:
EUR 3,13
A Estados Unidos de America
Librería: BooksRun, Philadelphia, PA, Estados Unidos de America
Hardcover. Condición: USED_GOOD. First Edition. Ship within 24hrs. Satisfaction 100% guaranteed. APO/FPO addresses supported. Nº de ref. del artículo: 0671723278-11-1
Cantidad disponible: 1 disponibles
Librería: Better World Books, Mishawaka, IN, Estados Unidos de America
Condición: USED_GOOD. Used book that is in clean, average condition without any missing pages. Nº de ref. del artículo: 720944-6
Cantidad disponible: 1 disponibles
Librería: SecondSale, Montgomery, IL, Estados Unidos de America
Condición: USED_GOOD. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc. Nº de ref. del artículo: 00067427192
Cantidad disponible: 2 disponibles
Librería: SecondSale, Montgomery, IL, Estados Unidos de America
Condición: USED_FAIR. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc. Nº de ref. del artículo: 00065912124
Cantidad disponible: 1 disponibles
Librería: Blue Vase Books, Interlochen, MI, Estados Unidos de America
Condición: USED_GOOD. The item shows wear from consistent use, but it remains in good condition and works perfectly. All pages and cover are intact (including the dust cover, if applicable). Spine may show signs of wear. Pages may include limited notes and highlighting. May NOT include discs, access code or other supplemental materials. Nº de ref. del artículo: 31URM800GAI6_ns
Cantidad disponible: 1 disponibles
Librería: Books Unplugged, Amherst, NY, Estados Unidos de America
Condición: USED_FAIR. Buy with confidence! Book is in acceptable condition with wear to the pages, binding, and some marks within 1.6. Nº de ref. del artículo: bk0671723278xvz189zvxacp
Cantidad disponible: 1 disponibles
Librería: Book Deals, Tucson, AZ, Estados Unidos de America
Condición: USED_GOOD. Good condition. This is the average used book, that has all pages or leaves present, but may include writing. Book may be ex-library with stamps and stickers. 1.6. Nº de ref. del artículo: 353-0671723278-gdd
Cantidad disponible: 1 disponibles
Librería: SecondSale, Montgomery, IL, Estados Unidos de America
Condición: USED_FAIR. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc. Nº de ref. del artículo: 00072660871
Cantidad disponible: 1 disponibles
Librería: Ergodebooks, Houston, TX, Estados Unidos de America
Hardcover. Condición: USED_GOOD. First Edition. An inside account of the start-up of a biotechnology company describes its struggle to bring a lifesaving drug to market, discussing the risky financing and profiling the venture capitalists involved. 30,000 first printing. Nº de ref. del artículo: SONG0671723278
Cantidad disponible: 1 disponibles
Librería: Charing Cross Road Booksellers, Canton, GA, Estados Unidos de America
Hardcover. Condición: USED_NEARFINE. Estado de la sobrecubierta: As New. First Edition. First Edition, First Printing. Red Cloth and Grey Board Covers with Silver Lettering to spine; front board has a small soiled area near upper left center; Red Endpapers; Book Interior is clean and tight; 8vo; 445 pages; indexed; dustjacket is protected by a mylar wrapper and is clean and bright with no noted defects. Nº de ref. del artículo: 20030991
Cantidad disponible: 1 disponibles